# A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

> **NCT02585440** · PHASE1 · COMPLETED · sponsor: **ContraVir Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Infectious Disease

## Interventions

- **DRUG:** CMX157
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02585440
- **Lead sponsor:** ContraVir Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585440, "A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02585440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*